

## **SUMMARY OF PRODUCTS CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Gleptosil 200mg/ml solution for injection

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

#### **Active Substance:**

|                            |            |
|----------------------------|------------|
| Iron                       | 200 mg/ml  |
| (as gleptoferron complex). | 498 mg/ml) |

#### **Excipients:**

|        |         |
|--------|---------|
| Phenol | 5 mg/ml |
|--------|---------|

For the full list of excipients see  
Section 6.1

### **3. PHARMACEUTICAL FORM**

Solution for injection.

A dark brown, slightly viscous, sterile, colloidal, aqueous solution

### **4. CLINICAL PARTICULARS**

#### **4.1 Target species**

Neonatal pigs

#### **4.2 Indications for use, specifying the target species**

Neonatal pigs:

For the prevention and treatment of iron deficiency anaemia.

#### **4.3 Contraindications**

None

#### **4.4 Special warnings for each target species**

None

#### **4.5 Special precautions for use**

i) Special precautions for use in animals

ii) Normal aseptic injection techniques should be practised.  
Special precautions for the person administering the veterinary medicinal product to animals

Care should be taken to avoid accidental self injection. In the event of accidental self injection seek medical advice. Wash hands after use.

iii) Other precautions

The sachet should not be opened until the product is required for use.  
Avoid the introduction of contamination during use.

#### **4.6 Adverse reactions (frequency and seriousness)**

There are normally no undesirable side effects associated with the use of the product. Its use does not result in permanent staining of the injected muscle tissue.

#### **4.7 Use during pregnancy, lactation or lay**

Not applicable

#### **4.8 Interaction with other medicinal products and other forms of interaction**

There are no known interactions between the product and other medicaments. There are no known other forms of interaction. Do not mix with other products prior to administration.

#### **4.9 Amount to be administered and administration route**

Use only automatic syringe equipment

Swab the septum before use. The product is administered as a single 1 mL (200 mg iron) dose by deep intramuscular injection into the hind limb midway between the stifle joint and the base of the tail. Injections should be administered as follows:

FOR THE PREVENTION OF IRON DEFICIENCY ANAEMIA: not later than the third day of life. FOR THE TREATMENT OF IRON DEFICIENCY ANAEMIA: at the onset of clinical anaemia, normally within the first three weeks of life.

For 100 & 250 ml plastic vials: as the vial cannot be broached more than 20 times, use of automatic syringe equipment is recommended.

For 100 ml collapsible vial: as the vial cannot be broached more than 4 times, the use of automatic syringe equipment is recommended.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

Overdosage with the product is unlikely to result in signs of intoxication.

#### **4.11 Withdrawal period**

MEAT AND OFFAL: ZERO DAYS.

### **5. PHARMACOLOGICAL PROPERTIES**

**Pharmacotherapeutic group:** Antianaemic preparations, Iron preparations, Iron trivalent, parenteral preparations

**ATCVet Code:** QBO3AC

#### **5.1 Pharmacodynamic properties**

Injectable iron-carbohydrate complexes are established haematinic agents in veterinary medicine. Following intramuscular injection, the complex is absorbed and metabolised to release the iron for utilisation and/or storage in accordance with the nutritional status of the animal. In iron deficient states, the iron is utilised for the synthesis of haemoglobin and other iron-containing molecules. Excess iron is stored principally in the liver.

#### **5.2 Pharmacokinetic properties**

Absorption of the product has been shown to be rapid. Over 95% of the administered iron (1mL/200 mg iron administered at three days of age) was absorbed by 24 hours after injection. Use of the product does not result in permanent staining of the injected muscle tissue.

#### **5.3 Environmental properties**

Not applicable

### **6. PHARMACEUTICAL PARTICULARS**

#### **6.1. List of excipients**

Phenol  
Sodium chloride  
Water for injections

#### **6.2. Major incompatibilities**

None known

### **6.3. Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale in 100 ml collapsible vial: 2 years.

Shelf life after opening the immediate packaging: 28 days Shelf-life of the veterinary medicinal product as packaged for sale in 100 & 250 ml multilayer plastic vials: 3 years.

### **6.4. Special precautions for storage**

Do not store above 25°C. Protect from light.

### **6.5. Nature and composition of immediate packaging**

100 mL clear colourless low-density polyethylene collapsible bottles with grey chlorbutyl rubber bung with aluminium overseal.

### **6.6. Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Ceva Animal Health Ltd  
Explorer House  
Mercury Park  
Wycombe Lane  
Wooburn Green  
High Wycombe  
Buckinghamshire  
HP10 0HH  
United Kingdom

## **8. MARKETING AUTHORISATION NUMBER**


Vm 15052/4079

## **9. DATE OF FIRST AUTHORISATION**

30 August 1995

## **10. DATE OF REVISION OF THE TEXT**

October 2022



Approved: 06 October 2022